Description
PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis
Article: PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis
€3.03
Related products
-
Article: Highlights in urologic cancer
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart
